FDA OKs Elacestrant for ESR1+ Advanced, Metastatic Breast Cancer ...Middle East

News by : (Medscape) -
The phase 3 data showed a 2-month progression-free survival benefit with elacestrant versus fulvestrant or an aromatase inhibitor. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA OKs Elacestrant for ESR1+ Advanced, Metastatic Breast Cancer )

Also on site :

Most Viewed News
جديد الاخبار